Overview

To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 300 mg Capsule Fed Conditions

Status:
Completed
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
To demonstrate the relative bioequivalence of Cefdinir and Omnicel 300 mg capsule fed conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Sandoz
Treatments:
Cefdinir
Cephalosporins